#USA #San Diego #GELITA #MEDELLAPRO #VACCIPRO

GELITA's Advances in Biomedical Excipients at BIO International 2026

GELITA, the global frontrunner in collagen protein solutions, is set to impress attendees at BIO International 2026 in San Diego with its latest advancements in excipient technology. The company is acclaimed for its expertise in gelatin and collagen peptides, which are vital in developing safe, effective, and sustainable applications for pharmaceutical and medical devices.

Introduction of Excipient Innovations

GELITA's portfolio now features cutting-edge Endotoxin Controlled Excipients (ECE) designed to meet the growing demands of the biomedical landscape. These carefully formulated excipients ensure safety, biocompatibility, and compliance with regulatory standards, making them ideal for diverse applications such as drug delivery, vaccine stabilization, tissue engineering, and regenerative medicine. Researchers and manufacturers will particularly benefit from these high-purity ingredients that are essential to life-saving therapies.

Focus on MEDELLAPRO® and VACCIPRO®

Among the highlights at the conference will be GELITA's two flagship products: MEDELLAPRO® and VACCIPRO®.

• - MEDELLAPRO® Gelatin: This gelatin stands out due to its strong biocompatibility and flexibility in formulation. It is invaluable for creating advanced biomedical products, including surgical sealants, hemostatic agents, and scaffolds for drug delivery systems.

• - VACCIPRO® Collagen Peptides: Designed for stabilizing vaccines and injectables, VACCIPRO® boasts a low allergenic profile, high tolerability, and the capability to protect sensitive molecules during the manufacturing process.

MEDELLAPRO® Ultra Low Endotoxin Innovation

Another significant highlight is the introduction of MEDELLAPRO® Ultra Low Endotoxin gelatin, which features an impressive reduction to less than 10 endotoxin units per gram. This new standard of purity is essential for sensitive biomedical applications, enabling the creation of highly reproducible biocompatible hydrogels. It offers researchers and manufacturers a reliable ingredient for projects demanding stringent safety and quality metrics.

Advancing Biotechnological Processes

GELITA is committed to sustainability and innovation in the biotech sector, as evidenced by its ongoing efforts to develop animal-free, recombinant collagen proteins. These breakthroughs signal a resource-efficient and sustainable future for biomedical applications. At the conference, GELITA will host an enlightening scientific presentation:

Topic: The Role of Non-Animal Recombinant Collagen Proteins in Biomedical Applications

Presenter: Dr. Michelle Montgomery, Ph.D. in Biochemistry and Molecular Biology, Senior Manager RD, GELITA

Date & Time: Tuesday, June 23, 2026, at 2:45 PM – Theatre 4

This session will delve into the significance of these advancements, from their roles in vaccine stabilization to their potential in creating artificial organs.

Experience GELITA at the Conference

Attendees are encouraged to visit GELITA at Booth 3335-DF in the German Pavilion to explore how MEDELLAPRO® and VACCIPRO® are revolutionizing vaccine development, medical devices, and the broader biomedical innovation landscape.

About GELITA

Established for over 150 years, GELITA excels in manufacturing and marketing collagen proteins. With its headquarters in Eberbach, Germany, the company is deeply committed to delivering high-standard products and sophisticated solutions to its global customer base. With a presence in more than twenty locations, GELITA offers state-of-the-art know-how and expertise tailored to the needs of its clients across food, pharmaceutical, health, and nutrition markets.

With GELITA leading the charge towards innovative medicine, the future of biomedical applications looks promising.